Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003323 · ClinicalTrials.gov registry record · Phase 2
Hormone Therapy in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT00003323 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 101 participants.
The verdict
NCT00003323, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
RATIONALE: Male hormones can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide and finasteride may fight prostate cancer by reducing the production of male hormones. PURPOSE: Phase II trial to study the effectiveness of flutamide and finasteride in treating prostate cancer patients with high PSA levels who were previously treated with radiation therapy or radical prostatectomy.
Interventions
- OTHER quality-of-life assessment
- DRUG flutamide
- DRUG finasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 1998-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003323
The ClinicalTrials.gov registry entry for NCT00003323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which quality-of-life assessment is the first listed.
NCT00003323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003323 about?
NCT00003323 is a clinical study titled "Hormone Therapy in Treating Patients With Prostate Cancer". RATIONALE: Male hormones can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide and finasteride may fight prostate cancer by reducing the production of male hormones. PURPOSE: Phase II trial to study the effectiveness of flutamide and finasteride in treating prostate can...
What is the current status of trial NCT00003323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 1998-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00003323?
The interventions under investigation include: quality-of-life assessment (OTHER), flutamide (DRUG), finasteride (DRUG).
Who is sponsoring clinical trial NCT00003323?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.